Risk Factors for Development and Severity of COVID-19 in COPD Patients

Risk Factors for Development and Severity of COVID-19 in COPD Patients

The impact that COVID-19 could have on patients with COPD is a real concern. In this study we evaluated, in a cohort of longitudinally followed COPD subjects, the incidence of COVID-19, seeking for possible risk factors and prognostic factors predicting the clinical outcome. In our cohort of 370 pat...

Full description

Bibliographic Details
Main Authors: Matteo Bonato, Umberto Semenzato, Mariaenrica Tinè, Erica Bazzan, Marco Damin, Davide Biondini, Alvise Casara, Micaela Romagnoli, Graziella Turato, Manuel G. Cosio, Marina Saetta, Simonetta Baraldo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Medicine
Subjects:
COVID-19
COPD comorbidities
clinical outcome
emphysema
DLCO
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.714570/full
id doaj-d80bd56cf5e344dda4879b873e348b76
record_format Article
spelling doaj-d80bd56cf5e344dda4879b873e348b762021-08-09T05:27:08ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.714570714570Risk Factors for Development and Severity of COVID-19 in COPD PatientsMatteo Bonato0Matteo Bonato1Umberto Semenzato2Mariaenrica Tinè3Erica Bazzan4Marco Damin5Davide Biondini6Alvise Casara7Micaela Romagnoli8Graziella Turato9Manuel G. Cosio10Manuel G. Cosio11Marina Saetta12Simonetta Baraldo13Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyPulmonology Unit, Ospedale Ca' Foncello, Azienda Unità Locale Socio Sanitaria 2 (AULSS2) Marca Trevigiana, Treviso, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyPulmonology Unit, Ospedale Ca' Foncello, Azienda Unità Locale Socio Sanitaria 2 (AULSS2) Marca Trevigiana, Treviso, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyRespiratory Division, Meakins-Christie Laboratories, McGill University, Montreal, QC, CanadaDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, ItalyThe impact that COVID-19 could have on patients with COPD is a real concern. In this study we evaluated, in a cohort of longitudinally followed COPD subjects, the incidence of COVID-19, seeking for possible risk factors and prognostic factors predicting the clinical outcome. In our cohort of 370 patients (followed for 5.3 ± 2.7 years), 22 developed COVID-19 (COPD/COVID-19+) between February/November 2020 (5.9%). Cardio-metabolic conditions (hypertension, dyslipidemia, obesity, diabetes) but not respiratory abnormalities (FEV1, DLCO, emphysema and exacerbation history), were risk factors for development of COVID-19 in COPD patients. Out of the 22 COPD/COVID-19+ patients, 10 needed intensive care. Low DLCO and emphysema, but also metabolic comorbidities, were related to the need for intensive care.https://www.frontiersin.org/articles/10.3389/fmed.2021.714570/fullCOVID-19COPD comorbiditiesclinical outcomeemphysemaDLCO
collection DOAJ
language English
format Article
sources DOAJ
author Matteo Bonato
Matteo Bonato
Umberto Semenzato
Mariaenrica Tinè
Erica Bazzan
Marco Damin
Davide Biondini
Alvise Casara
Micaela Romagnoli
Graziella Turato
Manuel G. Cosio
Manuel G. Cosio
Marina Saetta
Simonetta Baraldo
spellingShingle Matteo Bonato
Matteo Bonato
Umberto Semenzato
Mariaenrica Tinè
Erica Bazzan
Marco Damin
Davide Biondini
Alvise Casara
Micaela Romagnoli
Graziella Turato
Manuel G. Cosio
Manuel G. Cosio
Marina Saetta
Simonetta Baraldo
Risk Factors for Development and Severity of COVID-19 in COPD Patients
Frontiers in Medicine
COVID-19
COPD comorbidities
clinical outcome
emphysema
DLCO
author_facet Matteo Bonato
Matteo Bonato
Umberto Semenzato
Mariaenrica Tinè
Erica Bazzan
Marco Damin
Davide Biondini
Alvise Casara
Micaela Romagnoli
Graziella Turato
Manuel G. Cosio
Manuel G. Cosio
Marina Saetta
Simonetta Baraldo
author_sort Matteo Bonato
title Risk Factors for Development and Severity of COVID-19 in COPD Patients
title_short Risk Factors for Development and Severity of COVID-19 in COPD Patients
title_full Risk Factors for Development and Severity of COVID-19 in COPD Patients
title_fullStr Risk Factors for Development and Severity of COVID-19 in COPD Patients
title_full_unstemmed Risk Factors for Development and Severity of COVID-19 in COPD Patients
title_sort risk factors for development and severity of covid-19 in copd patients
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-08-01
description The impact that COVID-19 could have on patients with COPD is a real concern. In this study we evaluated, in a cohort of longitudinally followed COPD subjects, the incidence of COVID-19, seeking for possible risk factors and prognostic factors predicting the clinical outcome. In our cohort of 370 patients (followed for 5.3 ± 2.7 years), 22 developed COVID-19 (COPD/COVID-19+) between February/November 2020 (5.9%). Cardio-metabolic conditions (hypertension, dyslipidemia, obesity, diabetes) but not respiratory abnormalities (FEV1, DLCO, emphysema and exacerbation history), were risk factors for development of COVID-19 in COPD patients. Out of the 22 COPD/COVID-19+ patients, 10 needed intensive care. Low DLCO and emphysema, but also metabolic comorbidities, were related to the need for intensive care.
topic COVID-19
COPD comorbidities
clinical outcome
emphysema
DLCO
url https://www.frontiersin.org/articles/10.3389/fmed.2021.714570/full
work_keys_str_mv AT matteobonato riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT matteobonato riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT umbertosemenzato riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT mariaenricatine riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT ericabazzan riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT marcodamin riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT davidebiondini riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT alvisecasara riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT micaelaromagnoli riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT graziellaturato riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT manuelgcosio riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT manuelgcosio riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT marinasaetta riskfactorsfordevelopmentandseverityofcovid19incopdpatients
AT simonettabaraldo riskfactorsfordevelopmentandseverityofcovid19incopdpatients
_version_ 1721215253667119104

Similar Items